Search research articles
Contact Us
Filters
Showing results (121-130 of 178) with videos related to
Page
of 18
Sort By:
Nuclear Medicine and Biology
|
October 9, 2007
Challenges in clinical studies with multiple imaging probes
Kenneth A Krohn, Finbarr O'Sullivan, John Crowley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 14, 2003
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504
David R Gandara, Kari Chansky, Kathy S Albain, et al.
Blood
|
April 10, 2007
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
Frits van Rhee, Vanessa Bolejack, Klaus Hollmig, et al.
Haematologica
|
June 27, 2012
Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data
Sarah Waheed, Alan Mitchell, Saad Usmani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2009
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124
Primo N Lara, Ronald Natale, John Crowley, et al.
Blood
|
June 8, 2012
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance
Saad Z Usmani, Rachel Sexton, Antje Hoering, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee
Lesley Seymour, S Percy Ivy, Daniel Sargent, et al.
British Journal of Haematology
|
May 11, 2007
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics
John D Shaughnessy, Jeffrey Haessler, Frits van Rhee, et al.
Haematologica
|
May 30, 2013
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma
Xenofon Papanikolaou, Jackie Szymonifka, Adam Rosenthal, et al.
Conservation Biology : the Journal of the Society for Conservation Biology
|
February 23, 2017
Transforming conservation science and practice for a postnormal world
Matthew J Colloff, Sandra Lavorel, Lorrae E van Kerkhoff, et al.
Page
of 18
Search research articles
Search
Showing results (121-130 of 178) with videos related to
Sort By:
Page
of 18
Nuclear Medicine and Biology
|
October 9, 2007
Challenges in clinical studies with multiple imaging probes
Kenneth A Krohn, Finbarr O'Sullivan, John Crowley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 14, 2003
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504
David R Gandara, Kari Chansky, Kathy S Albain, et al.
Blood
|
April 10, 2007
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
Frits van Rhee, Vanessa Bolejack, Klaus Hollmig, et al.
Haematologica
|
June 27, 2012
Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data
Sarah Waheed, Alan Mitchell, Saad Usmani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2009
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124
Primo N Lara, Ronald Natale, John Crowley, et al.
Blood
|
June 8, 2012
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance
Saad Z Usmani, Rachel Sexton, Antje Hoering, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee
Lesley Seymour, S Percy Ivy, Daniel Sargent, et al.
British Journal of Haematology
|
May 11, 2007
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics
John D Shaughnessy, Jeffrey Haessler, Frits van Rhee, et al.
Haematologica
|
May 30, 2013
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma
Xenofon Papanikolaou, Jackie Szymonifka, Adam Rosenthal, et al.
Conservation Biology : the Journal of the Society for Conservation Biology
|
February 23, 2017
Transforming conservation science and practice for a postnormal world
Matthew J Colloff, Sandra Lavorel, Lorrae E van Kerkhoff, et al.
Page
of 18